EU animal tissue rule enforcement threatens existing products
This article was originally published in Clinica
There is a risk that a large number of medical device companies will be forced to remove from the EU market on September 30 products that have been manufactured utilising animal tissues. It seems that the deadline for meeting the EU Directive 2003/32/EC, introducing detailed specifications for such products within the context of the Medical Devices Directive, is not going to be tenable for the 200 or so products that will need to comply.
You may also be interested in...
Oncologic Drugs Advisory Committee votes 6-5 that ramucirumab’s benefit/risk profile is favorable in first-line lung cancer, but 13-2 that pivotal trial data do not support approval of Steba’s vascular-targeted, photodynamic therapy for low-risk prostate cancer.
Plaintiff Peter Lurie, former US FDA associate commissioner, expects results of hundreds of clinical trials of approved drugs will become available under ruling against HHS; co-plaintiff sought eteplirsen study data.